The current study was performed to evaluate the prognostic value of laboratory parameters and geriatric assessment (GA) in addition to a baseline model with clinical information regarding overall survival (OS) in patients with cancer. METHODS: GA was systematically performed in patients aged ≥70 years. The baseline model consisted of age, tumor type, and stage of disease. The incremental prognostic values of the GA as a whole (10-item GA) and laboratory parameters were assessed separately and combined. The parameters included hemoglobin (Hb), albumin, C-reactive protein (CRP), and the Glasgow Prognostic Score (GPS). Analyses were conducted with continuous and dichotomized variables. Cox models were compared based on Akaike information criterion (ΔAIC) and their discriminatory ability was assessed using the concordance probability estimate (CPE). RESULTS: A total of 328 patients were considered for this analysis. The baseline model had a CPE of 0.725. The addition of CRP, albumin, and Hb combined resulted in the best performing model (ΔAIC: 40.12 and CPE: 0.757) among the laboratory parameters. However, the 10-item GA improved the baseline model even more (ΔAIC: 46.03 and CPE: 0.769). Similar results were observed in the analysis with dichotomous variables. The addition of the 3 laboratory parameters (CRP, albumin, and Hb) improved the CPE by 1.4% compared with the baseline model already extended with the 10-item GA. The CPE increase (1.7%) was the highest with the GPS in the analysis with dichotomous variables. CONCLUSIONS: GA appears to add slightly more prognostic information than laboratory parameters in addition to clinical information. The laboratory parameters have an additional prognostic value beyond clinical and geriatric information. Cancer 2018;124:3764-3775.
INTRODUCTION
The implementation of geriatric screening and geriatric assessment (GA) in daily oncology practice is feasible and relevant. 1 To obtain a better view of the global health status of the patient, GA includes the assessment of social needs, functional status, comorbidity and medication use, cognitive and psychological status, and nutritional status. 2 One of the aims of the GA-based approach is to improve the estimation of life expectancy, which sometimes is a difficult task although very important in the treatment decision-making process. Quick online tools are available that can help to estimate the life expectancy of a patient in the general population. 3 However, these tools are not entirely suitable in geriatric oncology. In our recent work, we demonstrated that geriatric screening and GA provide additional prognostic information for overall survival (OS) in addition to clinical information in older patients with a solid tumor. 4 Although the GA is currently the best approach with which to estimate a patient's degree of frailty, many efforts are made to identify suitable biomarkers with which to measure biological age or frailty and to evaluate their predictive value for clinical outcomes such as mortality. 5, 6 Although many "aging biomarkers" for biological age have been proposed in geriatric oncology, to the best of our knowledge none has achieved a sufficient evidence base to date for use in routine clinical practice. Given the complexity of the aging process, it is likely that Cancer September 15, 2018 the best approach would be to work with a combination of geriatric information and biomarkers in addition to clinical information to aid in treatment decision making. Commonly measured laboratory blood values, not necessarily aging biomarkers, also might be interesting for this purpose. A study conducted in individuals aged 85 years from the general population demonstrated that a profile of 7 routine blood measurements predicted 5-year mortality as accurately as the known predictors of gait speed and instrumental activities of daily living (IADL). 7 For patients with cancer, various studies have identified several blood values routinely measured at the time of diagnosis as prognostic factors for OS. For example, in a recent study, a score was developed to improve the estimation of survival in patients with newly diagnosed brain metastases based solely on standard clinical blood values. 8 In the current study, we will focus on hemoglobin (Hb), albumin, and C-reactive protein (CRP). Their prognostic value for OS has been shown in a range of tumor types independent of other prognostic factors. [9] [10] [11] Simple inflammatory-based scores also have received much interest in the assessment of prognosis over the past few years. Three composite scores that combine CRP and albumin values will be included in this study: 1) the Glasgow Prognostic Score (GPS) 12 ; 2) the modified GPS (mGPS) 13 ; and 3) the CRP/albumin ratio. Their prognostic value for mortality has been shown in multiple studies with various types of cancer in different settings. [14] [15] [16] The objective of the current study was to compare the added prognostic value of the aforementioned laboratory parameters (Hb, albumin, and CRP) and the composite scores (GPS, mGPS, and the CRP/ albumin ratio) with the added prognostic value of GA and to evaluate their combined prognostic value for OS in addition to clinical information in patients with cancer.
MATERIALS AND METHODS

Design
The current study was part of a prospective, multicenter, observational study with 763 patients with a solid tumor that evaluated the added prognostic value of screening, individual GA components, and 2 GA summaries for OS to a baseline model of clinical information. 4 This study has been reported extensively previously. In short, the GA-based approach was implemented in routine oncology practice in 2 academic hospitals in Belgium (Universitair Ziekenhuis Brussel and Universitaire Ziekenhuizen Leuven) between October 2009 and July 2011. Patients aged ≥70 years were included during a hospital visit at the time of diagnosis or at the time of disease progression/ recurrence, when a treatment decision had to be made. Inclusion was limited to patients with the following 5 tumor types: breast, colorectal, ovarian, lung, and prostate cancer. All data were collected by trained health care workers in both centers. 17 The study was approved by the ethical committees of both participating hospitals.
Laboratory Parameters
Data regarding serum Hb, serum albumin, and CRP were used from routinely collected blood samples shortly before or after the date of GA. The 3 laboratory parameters were categorized for descriptive statistics. Local laboratory ranges were used from both participating hospitals to dichotomize the laboratory values. Because these did not correspond, different cutoff values were used for each hospital.
Hb was dichotomized into below the lower limit of normal (<LLN) and ≥LLN. The LLN was 12.0 g/ dL or 11.8 g/dL depending on the hospital. Because the local laboratory ranges did not distinguish cutoff values for men and women, we used the 1968 World Health Organization (WHO) criteria (Hb < 12.0 g/dL for men and Hb <11.8 g/dL for women) but also alternative cutoff values proposed by Beutler and Waalen 18 for older white adults (Hb < 13.2 g/dL for men and Hb <12.2 g/dL for women) to evaluate whether sex-specific cutoff values would improve the prognostic value of Hb.
Albumin was dichotomized into <LLN and ≥LLN, with an LLN of 35.0 g/L or 37.0 g/L. CRP as a continuous variable was analyzed per 10-point increase to allow for a more practical interpretation of the results. CRP also was categorized into elevated values with cutoff values of >5.0 mg/L or ≥ 5.0 mg/L depending on the hospital, and normal values.
The inflammatory-based composite score, GPS (score range, 0-2), was defined as follows: score 0 indicated CRP ≤ 10 mg/dL and albumin ≥ 35.0 g/L; score 1 indicated CRP > 10 mg/L or albumin < 35.0 g/L; and score 2 indicated CRP > 10 mg/L and albumin < 35.0 g/L. 12 The only difference between the GPS and the mGPS is that the mGPS does not consider hypoalbuminemia (<35.0 g/L) in the allocation of score 1. 13 
Geriatric Assessment
The GA included 10 components based on the 2014 International Society of Geriatric Oncology (SIOG) recommendation guideline for GA 2 : social data with living situation, functional status as assessed by the Activities of Cancer September 15, 2018 Daily Living (ADL) by Katz et al 19 and by Lawton and Brody's Instrumental Activities of Daily Living (IADL) 20 ; fall history within the last year 21 ; fatigue as assessed by the Mobility-Tiredness Test (MOB-T) 22 ; mental status as assessed by the Mini-Mental State Examination (MMSE) 23 and Geriatric Depression Scale (GDS-15) 24 ; nutritional status as assessed by the Mini Nutritional Assessment-Short Form (MNA-SF) 25 ; comorbidities as assessed by the Charlson Comorbidity Index (CCI) 26 ; and a polypharmacy assessment. 27 When taken together, this 10-item GA is a GA summary that integrates the results of every GA component mentioned above and thus captures the multidimensional GA as a whole evaluating the global health of the older patient with cancer. However, it does not calculate a global GA end score. In our previous article, we demonstrated that the 10-item GA provides more prognostic information than the individual GA components and screening tools because GA summaries are likely better at capturing the multidimensional process of aging. 4 Therefore, in the current study, we primarily compared the added prognostic value of the 10-item GA with that of laboratory parameters. However, for comparative reasons, we also included the individual GA components, the Leuven Oncogeriatric Frailty Score (LOFS) (also a GA summary), the G8, the Flemish version of the Triage Risk Screening Tool (fTRST), and the Eastern Cooperative Oncology Group performance status (ECOG PS) in the current analysis. The G8 (score range of 0-17; cutoff value of ≤ 14) and the fTRST (score range of 0-6; cutoff value of ≥ 1) are geriatric screening tools with which to identify patients who would benefit from a GA. [28] [29] [30] [31] The ECOG PS is frequently used in oncology to classify the performance status of patients. 32 The LOFS is a recently developed tool with which to summarize clinical frailty 4, 6 and integrates information from 5 GA components into a single global end score (range, 0-10). The following categories are included: severely frail (score of 0-2), frail (score of 3-4), vulnerable (score of 5-6), slightly vulnerable (score of 7-8) and fit (score of 9-10).
Statistical Analysis
Patient and clinical characteristics, screening tools, and GA results were compared between the groups of patients included and excluded from the main analysis by means of the chi-square test and the Mann-Whitney U test as appropriate. The median survival of the 2 groups was compared using the log-rank test.
Univariable Cox proportional hazards regression analyses were conducted to evaluate the prognostic value of laboratory parameters, screening tools, individual GA components, and the LOFS. Multivariable analyses also were performed to adjust for clinical information (age, stage of disease, and tumor type). OS was calculated from date of GA to the date of death from any cause or last follow-up for censored patients. Results were considered statistically significant at P<.05.
We performed Cox proportional hazards regression analyses to build multiple prognostic models. The baseline clinical model consisted of age as a continuous variable and tumor type and stage of disease as categorical variables. To assess the contribution of the laboratory parameters, the 10-item GA, and the 2 combined, each was added separately to the baseline model of clinical information. The goodness of fit of the nested models was compared using the likelihood-ratio test. We also added the individual GA components, the screening tools, and the LOFS into the analysis. Multicollinearity was assessed using the variance inflation factor and was not found to be present (variance inflation factors <3). The cox.zph function revealed that the proportional hazards assumption was not satisfied for age, albumin as a continuous variable, CRP and Hb as a dichotomous variable, and the (m)GPS in some of the multivariable models. We decided not to modify these models because the current study objective was to compare the performance of the examined models and not to adjust the construction of the models to get a better fit.
The discriminatory ability of each prognostic model was assessed using the concordance probability estimate (CPE). 33 The global fit of the Cox models was compared by means of the difference of the Akaike information criterion (AIC) of the baseline model and the extended model (ΔAIC). A higher ΔAIC value corresponded to a more explanatory and informative model.
Separate analyses were conducted with the GA components and laboratory parameters as continuous variables and as dichotomized variables whenever possible. Because the baseline model was identical in both analyses, we were able to quantify the expected loss of information and thus loss in prediction due to the dichotomization of the data. The LOFS was analyzed as a categorical variable and a continuous variable (per 1-point increase). The (m)GPS (score range of 0-2) was analyzed as a categorical variable but also as a continuous variable when calculating the hazard ratios (HRs) to obtain the risk-per-unit increase. All analyses were performed using SPSS statistical software (version 23; IBM Corporation, Armonk, New York) and R statistical software (version 3.3.3; R Foundation, Vienna, Austria).
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RESULTS
Patient Population
For more information regarding the total sample, we refer to our previous publication (cohort A, which consisted of 763 patients). 4 For the current study, a subgroup of 328 patients for whom information was available regarding the 3 laboratory parameters was considered. The median age of the patients was 77 years (range, 70-95 years). The most prevalent tumors were from the breast (38.4%), colorectum (35.4%), lung (15.5%), and prostate (6.4%). At the time of inclusion in the study, approximately 63.7% of patients had a newly diagnosed cancer, whereas 36.3% had disease progression or recurrence. With regard to comorbidity, 54.9% of patients had a score of ≥1 on the CCI. More details regarding patient demographics and clinical characteristics, including patients who were excluded from the analysis, are listed in Table 1 . The results of the GA are listed in Table 2 . The studied subgroup was more often male, had a different pattern of tumor types, had more advanced disease, and received less surgery but more frequent chemotherapy and radiotherapy than the group of patients excluded from the analysis (435 patients). The GA demonstrated that the studied subgroup more often had a geriatric risk profile according to the G8 and was more often depressed. Furthermore, the survival was significantly lower, with a median survival of 21 
Prognostic Value of Laboratory Parameters
Blood samples were collected on average 7.7 days (standard deviation, 10.0 days) from the date on which GA was performed. In total, 58.8% of the patients (193 patients) had an elevated CRP level, 28.4% (93 patients) had an albumin level <LLN, and 41.8% (137 patients) had a Hb level <LLN. For the GPS, 169 patients (51.5%) were allocated as score 0, 93 patients (28.4%) as score 1, and 66 patients (20.1%) as score 2. The results according to the mGPS were as follows: 178 patients as score 0 (54.3%), 84 patients as score 1 (25.6%), and 66 patients as score 2 (20.1%).
Kaplan-Meier plots from the 3 individual laboratory parameters and the GPS are shown in Figure 1 . The prognostic values of the laboratory parameters (CRP, albumin, and Hb) and the composite scores (GPS, mGPS, and the CRP/albumin ratio) are shown in Table 3 . Every laboratory-based parameter (continuous, dichotomized, and categorical) was found to be prognostic for OS in univariable and adjusted analyses. Results for the individual GA components, screening tools, and LOFS also are included in Table 3 .
We conducted additional analyses for Hb taking into account sex-specific cutoff values. This resulted in an additional 30 patients and 41 patients, respectively, who were categorized as having abnormal Hb values according to the WHO criteria and the alternative cutoff values proposed by Beutler and Waalen. 18 Their estimated HRs are included in Table 3 . 
Comparison of Prognostic Models
The baseline model had a good discriminatory ability with a CPE of 0.725. The added value of the laboratory parameters and GA are shown in Table 4 . Based on the CPE and AIC results, albumin performed better than CRP in the analyses with continuous and dichotomous variables. Both parameters clearly performed far better than Hb. The GPS (ΔAIC: 32.54 and CPE: 0.750) had the best performance compared with the 2 other composite scores (mGPS and CRP/albumin ratio), although not better than albumin as a continuous variable (ΔAIC: 34.22 and CPE: 0.755) or when all 3 continuous laboratory parameters (CRP, albumin, and Hb) were combined, which resulted in the best performing model among the models extended with laboratory parameters (ΔAIC: Results for the individual GA components, the LOFS, and the screening tools (G8, fTRST, and ECOG PS) are included in Table 4 for comparison. None of these models performed better than the best performing models with laboratory parameters. When comparing the individual GA components with the laboratory Cancer September 15, 2018 parameters, it is important to note that a model might have a better discriminatory ability (CPE) than another, whereas the prognostic information (ΔAIC) contained in that model might be lower. For example, nutritional status as measured by the MNA-SF as a continuous variable added more prognostic information than albumin (ΔAIC: 37.91 vs ΔAIC: 34.22), whereas the MNA-SF model had a lower CPE (CPE: 0.749 vs CPE: 0.755).
The analyses that evaluated the laboratory parameters in addition to the baseline model already extended with the 10-item GA demonstrated that the laboratory parameters had an added prognostic value beyond clinical and geriatric information. The results are summarized in Table 4 . We added the GPS and the mGPS, which are categorical variables, to the 2 analyses with the 10-item GA analyzed with continuous and dichotomous variables. In order of the ΔAIC results, the following models were found to have the best performance when analyzed with continuous variables: the models with CRP (ΔAIC:68.03 and CPE: 0.780), the 3 laboratory parameters combined (ΔAIC: 67.18 and CPE: 0.783), the CRP/albumin ratio (ΔAIC: 66.99 and CPE: 0.780), the GPS (ΔAIC: 66.22 and CPE:0.782). The following ranking was observed in the analyses with dichotomous variables: the models with the GPS (ΔAIC: 63.58 and CPE: 0.780), the mGPS (ΔAIC: 58.48 and CPE: 0.778), the 3 laboratory parameters combined (ΔAIC: 49.12 and CPE: 0.773), and CRP (ΔAIC: 48.28 and CPE: 0.771).
A visual overview of the improved performance of the models extended with the 3 laboratory parameters (CRP, albumin, and Hb) and the 10-item GA can be found in Figure 2 . The addition of every laboratory parameter improved the goodness of fit of each model, with the exception of Hb as a dichotomous variable beyond the model already extended with the 10-item GA. The small improvement with Hb was only significant when it was dichotomized according to the sex-specific cutoff values proposed by Beutler and Waalen (likelihood-ratio test, P = .04). 18 
DISCUSSION
CRP, Albumin, and Hb in Patients With Cancer
CRP levels increase in response to inflammation and are elevated in a variety of illnesses, including cancer. Inflammation markers such as CRP are also potential aging biomarkers because low-level increases in general/ nonspecific inflammation accompany aging (inflammaging). 5 A prognostic value of CRP with regard to mortality in older patients with cancer thus might be explained by processes related to the cancer and/or aging.
The 2 other commonly measured laboratory parameters studied herein, albumin and Hb, should be viewed less within the context of aging and more within the context of underlying diseases such as cancer. Serum albumin is generally used to assess nutritional status. However, both inflammation and malnutrition reduce albumin levels by decreasing its rate of synthesis. 10 Lower Hb levels or anemia are common in patients with cancer and can develop from multiple causes. In addition, when related to cancer itself, multiple mechanisms can interfere with normal erythrocyte production, but this usually is secondary to an imbalance of cytokines. 29 In the current study, anemia was unlikely to be related to cancer treatment because blood samples were used around the time of a treatment decision.
Regardless of the causes of changes in the levels of these 3 commonly measured laboratory parameters, the results of the current study confirm that CRP, albumin, Hb, and the composite scores based on CRP and albumin (GPS, mGPS, and the CRP/albumin ratio) are prognostic factors for OS independent of clinical information (age, stage of disease, and tumor type) in older patients with cancer.
Comparison of the Added Prognostic Value of Laboratory Parameters and GA
We previously demonstrated that the majority of individual GA components are prognostic factors for OS independent of clinical information. 4 Studies that evaluate the prognostic value of GA generally focus on the most prognostic individual GA components or on the best set of GA components. [36] [37] [38] [39] [40] In our previous analysis, we took a more extensive approach and also studied the added prognostic value of the GA as a whole (the 10-item GA) by comparing the performance of a baseline model of clinical information with models extended with geriatric information. 4 This allowed us, for example, to quantify the superior prognostic value of the GA as a whole compared with the individual GA components in addition to clinical information.
A comparison of the added prognostic value of the laboratory parameters and the individual GA components in the current study sometimes was difficult because the results varied depending if you look at the ΔAIC or CPE results and depending if you look at the analysis with continuous or dichotomous variables. Conversely, results occasionally were easy to interpret. From the individual GA components, only nutritional status (MNA-SF) was found to rival the performance of the best performing laboratory parameters in the analysis Cancer September 15, 2018 with continuous variables. Furthermore, as expected, the dichotomization of the laboratory parameters and the GA components significantly reduced the performance of the models. This is important to note because many studies dichotomize data and because many clinicians are used to working with categorized information. PS (ADL, IADL, and ECOG PS) is an important domain in the assessment of patients' global health status. IADL was found to be one of the most prognostic GA components in our analysis of the full sample (763 patients). 4 However, PS did not perform as well in this subgroup, regardless of the data type. A possible explanation might be that PS is more driven by tumor type and stage of disease compared with other GA components and that the more advanced disease (and different pattern of tumor types) observed in this subgroup of patients might have reduced the independent prognostic impact of PS whereas other GA components that reflect other aspects of the patient's global health status were less influenced. In this regard, we note that the inflammation-based composite scores, which also may be regarded as being driven by tumor characteristics, performed better than PS. The comparison of the composite scores GPS and mGPS with the other variables should be interpreted carefully. The (m)GPS is a score with 3 levels and was added unchanged into the analyses with continuous and dichotomous variables. This explains why the GPS performed within the same range as albumin and CRP in the analysis with continuous variables whereas it clearly performed better than albumin and CRP in the analysis with dichotomous variables. In the analysis with dichotomous variables, we also conducted additional analyses with Hb because the threshold for defining anemia has been the subject of considerable scientific debate. Various cutoff values are used in the literature. In the current study, we considered 2 alternative sex-specific cutoff values to examine whether this would improve the prognostic value of Hb. A small improvement was observed in the stratification of patients; however, the added prognostic value of Hb throughout the study was found to be inferior to that of the other laboratory parameters.
The comparison of the laboratory parameters with the 10-item GA demonstrates that the latter is superior based on ΔAIC and CPE results. The AIC is a more Cancer September 15, 2018 sensitive method than the CPE with which to rank different models; however, the CPE provides an interpretable measure of performance. According to the CPE results, the addition of the 10-item GA increased the performance of the baseline model by 4.4% whereas the best performing model with laboratory parameters (ie, with CRP, albumin, and Hb) resulted in a lower increase of 3.2% in the analysis with continuous variables. In the analysis with dichotomous variables, the GPS added more than the 3 laboratory parameters combined (ie, 2.5% vs 2.2%). However, the 10-item GA added more, with a CPE increase of 3.9%. In other words, the model with the 10-item GA was found to perform better than the best model incorporating laboratory parameters, with a CPE difference of 1.2% or 1.4% depending on the data type. Obviously, the laboratory parameters have the advantage of being objective, reproducible, inexpensive, and fast whereas the implementation of GA into routine practice requires the necessary time and resources. However, we emphasize that the GA-based approach is also important for other reasons within this context such as to estimate the risk of treatment-induced toxicity, to detect previously unknown health problems, and to allow for directed geriatric interventions that can improve therapy compliance and outcome.
Incremental Prognostic Value of Laboratory Parameters Beyond GA
The findings of the current study demonstrate that laboratory parameters and GA improve the estimation of life The (m)GPS was analyzed as a categorical variable in the left and right column whereas the 10-item GA was analyzed with continuous variables when possible and dichotomous variables, respectively.
Cancer September 15, 2018 expectancy separately. However, given the complexity of the processes related to aging, cancer, and their interaction, the combination of different types of information is likely to improve the accuracy of the assessment of prognosis. To the best of our knowledge, very few studies to date have evaluated the prognostic value of both GA and biomarkers for OS. Aaldriks et al studied patients with non-Hodgkin lymphoma by examining the HRs after entering individual GA components and biomarkers in a multivariable model. 41 A recent study from Honecker et al evaluated the simultaneous impact of GA and biomarkers in patients with breast cancer by selecting the best set of factors through elimination starting from a multivariable model incorporating all candidate parameters (backward stepwise analysis). 42 In the current study, we used another analytic approach because we were interested in the incremental value of biomarkers for OS. To the best of our knowledge, the current study is the first to compare the incremental value of different biomarkers beyond the GA as a whole. The results of the current analysis demonstrated that the laboratory parameters continued to add prognostic information beyond the model with both clinical information and the 10-item GA. As previously noted, differences occasionally were small and the ranking of the models depended on the AIC and CPE results. According to the more sensitive AIC results, CRP added the most prognostic information. However, the CPE increased the most when the combination of the 3 laboratory parameters was added, resulting in a CPE increase of 5.8% compared with the baseline model and an increase of 1.4% compared with the baseline model already extended with the 10-item GA. In the analysis with dichotomous variables, it was the GPS that was found to add the most in terms of both AIC and CPE results. The CPE increased by 5.6% compared with the baseline model and by 1.7% compared with the baseline model extended with the 10-item GA.
In theory, there exists some overlap in prognostic information provided by geriatric information and biomarkers (eg, nutritional status and albumin). Honecker et al suggested that there was nearly no overlap based on the variables retained in their final model for OS. 42 In the current study, we were able to investigate this more accurately when we placed the analyses in which the baseline model is extended with the laboratory parameters and the 10-item GA separately together with the analyses in which both are added simultaneously. To illustrate this with numbers from the analysis with continuous variables, the model extended with the 3 laboratory parameters combined (CRP, albumin, and Hb) improved the CPE by 3.2% (ΔAIC: 40.12) and when extended with the 10-item GA, it improved it by 4.4% (ΔAIC: 46.03). One might expect a CPE increase of 7.6% (ΔAIC: 86.15) when the baseline model is extended with both. However, when both the 3 laboratory parameters and the 10-item GA actually were added to the baseline model, the CPE increased by only 5.8% (ΔAIC: 67.18). Nevertheless, as quantified in the current study, the combination of geriatric information and biomarkers improves the estimation of life expectancy more than either separately. Cancer September 15, 2018 
Strengths and Limitations
The strengths of the current study include the relatively large sample size, the prospective study design, the many domains covered by the GA, the analysis approach, and the long follow-up. However, some considerations need to be taken into account when interpreting the results. Ideally, "aging" biomarkers should not be influenced by underlying health conditions and the timing of the blood collections is another possible confounding factor, thereby limiting their use in routine clinical practice. 5 In the current study, this pertains to CRP because CRP levels might be increased due to inflammatory reactions caused by the cancer or another underlying health condition but also due to, for example, recent surgery. However, we did work with blood samples that were taken at a fixed time (ie, shortly before or after GA) and therefore at the time of diagnosis or disease progression/ recurrence. Future studies with a more homogenous population and more detailed information regarding treatment should make a distinction between these 2 settings given the hypothesized pro-aging effects of many cancer treatments.
The findings of the current study are applicable to a population for which all 3 studied laboratory parameters are evaluated in routine practice. As demonstrated by the results presented herein, this subgroup is as expected more vulnerable and has a worse survival compared with the group of patients for whom all 3 laboratory parameters were not tested. Patients often were excluded from our analysis because the combination of CRP and albumin was not tested (reducing the sample size to 329 patients). However, additional analyses considering 1 laboratory parameter and thus larger sample sizes due to fewer missing data (CRP [501 patients], albumin [423 patients], and Hb [692 patients]) did not change our conclusions, which suggests that the results of the current study are also relevant for patients for whom all 3 laboratory parameters generally are not tested (see Supporting Information).
Furthermore, the heterogeneous population in the current study is a disadvantage because many relevant prognostic parameters are not captured but at the same time it is an advantage because it is representative of a larger cancer population.
